Molecure SA

Molecure SA maintains a strong liquidity position, with a current ratio of 5.79, indicating the company can easily cover its short-term liabilities with its current assets. The company holds PLN 17,077,630 in cash and equivalents, which is a significant portion of its total assets of PLN 108,785,150. The debt-to-equity ratio is low at 0.07, suggesting minimal leverage and a conservative capital structure.

Profitability metrics for Molecure are currently negative, with a return on equity of -7.27% and a return on assets of -6.29%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is negative at PLN -7,259,660, and the net income is also negative at PLN -6,839,250, reflecting ongoing operational losses.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risk if market conditions in its primary segment or region deteriorate.

Molecure's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The company's operating cash flow is negative at PLN -2,150,990, and its free cash flow is also negative at PLN -6,336,720, indicating that it is not generating sufficient cash from operations to fund its activities or growth initiatives.

The risk assessment for Molecure indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. However, the company's ongoing losses and negative cash flows suggest potential future liquidity challenges if the current financial performance does not improve.

Recent events, including analyst estimates, show a mixed outlook. The mean recommendation is 1.50, with one strong-buy and one buy rating, but no hold, sell, or strong-sell ratings. The mean EPS estimate is -2.90 PLN, which is significantly lower than the last actual EPS of -0.76 PLN, indicating a potential for further earnings deterioration.

Revenue surged 332% year-over-year to PLN 6.0 million in FY2026, demonstrating significant top-line growth momentum.

Net losses improved by 50.2% year-over-year, indicating a substantial reduction in the rate of financial deterioration.

Free cash flow improved by 56.3% year-over-year, suggesting better cash management or reduced capital expenditure needs.

Long-term debt decreased to PLN 5.3 million in FY2026, reflecting a deleveraging trend and improved balance sheet health.

The company posted a net loss of PLN 15.7 million in FY2026, resulting in a negative net margin of -240.48%.

Operating margin of -255.26% places the company in the bottom quartile compared to 258 biotechnology peers.

Free cash flow remains deeply negative at PLN -12.3 million, highlighting persistent cash burn despite recent improvements.

Cash conversion ratio of 0.31 is in the bottom quartile, indicating poor ability to convert revenue into cash.

High credit risk is flagged, suggesting potential difficulties in meeting financial obligations or securing favorable financing terms.

Revenue PLN 2.4M, +222,9% YoY; Operating income +83,0% YoY.

• ▍Revenue PLN 2.4M, +222,9% YoY
• ▍Operating income +83,0% YoY
• ▍Net income +83,8% YoY
• ▍Free cash flow +93,0% YoY
• ▍Net margin -70.7%

Revenue PLN 756.4k; Operating income -PLN 10.6M.

• ▍Revenue PLN 756.4k
• ▍Operating income -PLN 10.6M
• ▍Net margin -1414.7%

Revenue PLN 593.8k; Operating income -PLN 6.4M.

• ▍Revenue PLN 593.8k
• ▍Operating income -PLN 6.4M
• ▍Net margin -1054.8%

Revenue PLN 13.9k; Operating income -PLN 8.0M.

• ▍Revenue PLN 13.9k
• ▍Operating income -PLN 8.0M
• ▍Net margin -55427.3%

Revenue PLN 28.4k; Operating income -PLN 7.3M.

• ▍Revenue PLN 28.4k
• ▍Operating income -PLN 7.3M
• ▍Net margin -24048.0%

Revenue PLN 6.0M, +332,1% YoY; Operating income +48,8% YoY.

• ▍Revenue PLN 6.0M, +332,1% YoY
• ▍Operating income +48,8% YoY
• ▍Net income +50,2% YoY
• ▍Free cash flow +56,3% YoY
• ▍Net margin -260.8%

Revenue PLN 1.4M, −61,9% YoY; Operating income −0,6% YoY.

• ▍Revenue PLN 1.4M, −61,9% YoY
• ▍Operating income −0,6% YoY
• ▍Net income −11,1% YoY
• ▍Free cash flow −8,6% YoY
• ▍Net margin -2264.2%

Revenue PLN 3.7M, +126,5% YoY; Operating income −91,6% YoY.

• ▍Revenue PLN 3.7M, +126,5% YoY
• ▍Operating income −91,6% YoY
• ▍Net income −85,5% YoY
• ▍Free cash flow −49,7% YoY
• ▍Net margin -776.8%

Revenue PLN 1.6M, +38,1% YoY; Operating income −21,8% YoY.

• ▍Revenue PLN 1.6M, +38,1% YoY
• ▍Operating income −21,8% YoY
• ▍Net income −12,2% YoY
• ▍Free cash flow −16,6% YoY
• ▍Net margin -948.5%

Revenue PLN 1.2M; Operating income -PLN 13.8M.

• ▍Revenue PLN 1.2M
• ▍Operating income -PLN 13.8M
• ▍Net margin -1167.6%